{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:19:36Z","timestamp":1788376776040,"version":"build-2803163510"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>\n            <jats:italic>ETV6::RUNX1<\/jats:italic> leukemia is the second most common subtype of childhood B cell acute lymphoblastic leukemia (B-ALL). Although it generally has a low relapse risk, a significant proportion of B-ALL relapses occur within this subtype due to its relatively high incidence. Measurable residual disease at the end of induction therapy is a well-established biomarker predicting treatment outcomes, while no genomic biomarkers are routinely applied in clinics. In this study, we used multiomic data from <jats:italic>ETV6::RUNX1<\/jats:italic> leukemias to identify genomic features predictive of therapy response at disease presentation. In the deeply characterized sub-cohort we discovered that fast-responding cases frequently exhibited the APOBEC mutational signature and the gene expression signature of high cell cycle activity. In contrast, rearrangements of <jats:italic>IGK<\/jats:italic> genes were more frequent in slow responders. Additionally, response-related mutations were identified in transcriptional regulators and tumor suppressor genes (<jats:italic>INTS1, NF1, TP53<\/jats:italic>). Copy number analysis revealed that fast responders harbored more frequent deletions of chr12 p-arm, leading to transcriptomic changes affecting genes associated with induction therapy response (<jats:italic>KRAS<\/jats:italic>, <jats:italic>FKBP4<\/jats:italic>), while a shorter gain in chr12 was more common in slow responders. The identified genetic and transcriptomic markers of treatment sensitivity pave the way for improved disease classification at presentation, potentially improving clinical outcomes.<\/jats:p>","DOI":"10.1038\/s41375-025-02683-7","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:46:01Z","timestamp":1752137161000},"page":"2125-2139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Genomic determinants of therapy response in ETV6::RUNX1 leukemia"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4468-9877","authenticated-orcid":false,"given":"Laura","family":"Oksa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4446-015X","authenticated-orcid":false,"given":"Sanni","family":"Moisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2981-2582","authenticated-orcid":false,"given":"Khurram","family":"Maqbool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atte","family":"Nikkil\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buddika","family":"Jayasingha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5521-9216","authenticated-orcid":false,"given":"Artturi","family":"M\u00e4kinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Foroughi-Asl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuli","family":"Rounioja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Suhonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6436-9531","authenticated-orcid":false,"given":"Olga","family":"Krali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-3471","authenticated-orcid":false,"given":"Miikka","family":"Voutilainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4050-4935","authenticated-orcid":false,"given":"Mari","family":"Lahnalampi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisa","family":"Veps\u00e4l\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-5673","authenticated-orcid":false,"given":"Jesus","family":"Duque-Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-3058","authenticated-orcid":false,"given":"Julia","family":"Hauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8699-9959","authenticated-orcid":false,"given":"Jessica","family":"Nordlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-5439","authenticated-orcid":false,"given":"Valtteri","family":"Wirta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-0797","authenticated-orcid":false,"given":"Olli","family":"Lohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6190-3439","authenticated-orcid":false,"given":"Merja","family":"Hein\u00e4niemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2683_CR1","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1182\/blood.V94.3.1057.415k10_1057_1062","volume":"94","author":"JL Wiemels","year":"1999","unstructured":"Wiemels JL, Ford AM, Van Wering ER, Postma A, Greaves M. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood. 1999;94:1057\u201362.","journal-title":"Blood"},{"key":"2683_CR2","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.1073\/pnas.112218799","volume":"99","author":"H Mori","year":"2002","unstructured":"Mori H, Colman SM, Xiao Z, Ford AM, Healy LE, Donaldson C, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA. 2002;99:8242\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2683_CR3","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1182\/blood-2005-08-3451","volume":"107","author":"ML Loh","year":"2006","unstructured":"Loh ML, Goldwasser MA, Silverman LB, Poon WM, Vattikuti S, Cardoso A, et al. Prospective analysis of TEL\/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood. 2006;107:4508\u201313.","journal-title":"Blood"},{"key":"2683_CR4","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1182\/blood-2010-03-275347","volume":"117","author":"L Kuster","year":"2011","unstructured":"Kuster L, Grausenburger R, Fuka G, Kaindl U, Krapf G, Inthal A, et al. ETV6\/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood. 2011;117:2658\u201367.","journal-title":"Blood"},{"key":"2683_CR5","doi-asserted-by":"publisher","first-page":"e883","DOI":"10.1097\/HS9.0000000000000883","volume":"7","author":"U Nor\u00e9n-Nystr\u00f6m","year":"2023","unstructured":"Nor\u00e9n-Nystr\u00f6m U, Andersen MK, Barbany G, Dirse V, Eilert-Olsen M, Engvall M, et al. Genetic Subtypes and Outcome of Patients Aged 1 to 45 Years Old With Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Trial. Hemasphere. 2023;7:e883.","journal-title":"Hemasphere"},{"key":"2683_CR6","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1182\/blood.V96.8.2691","volume":"96","author":"E Coustan-Smith","year":"2000","unstructured":"Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691\u20136.","journal-title":"Blood"},{"key":"2683_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/cncr.11043","volume":"97","author":"J Madzo","year":"2003","unstructured":"Madzo J, Zuna J, Muz\u00edkov\u00e1 K, Kalinov\u00e1 M, Krejc\u00ed O, Hrus\u00e1k O, et al. Slower molecular response to treatment predicts poor outcome in patients with TEL\/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer. 2003;97:105\u201313.","journal-title":"Cancer"},{"key":"2683_CR8","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1200\/JCO.2008.20.8934","volume":"27","author":"G Basso","year":"2009","unstructured":"Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27:5168\u201374.","journal-title":"J Clin Oncol"},{"key":"2683_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","volume":"36","author":"D O\u2019Connor","year":"2018","unstructured":"O\u2019Connor D, Enshaei A, Bartram J, Hancock J, Harrison CJ, Hough R, et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2018;36:34\u201343.","journal-title":"J Clin Oncol"},{"key":"2683_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13052-018-0541-6","volume":"44","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zeng HM, Zhang LP. ETV6\/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol. Ital J Pediatr. 2018;44:94.","journal-title":"Ital J Pediatr"},{"key":"2683_CR11","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","volume":"107","author":"C Saygin","year":"2022","unstructured":"Saygin C, Cannova J, Stock W, Muffly L. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022;107:2783\u201393.","journal-title":"Haematologica"},{"key":"2683_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0165-4608(01)00518-0","volume":"130","author":"P Andreasson","year":"2001","unstructured":"Andreasson P, Schwaller J, Anastasiadou E, Aster J, Gilliland DG. The expression of ETV6\/CBFA2 (TEL\/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genet Cytogenet. 2001;130:93\u2013104.","journal-title":"Cancer Genet Cytogenet"},{"key":"2683_CR13","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2003-10-3695","volume":"103","author":"M Morrow","year":"2004","unstructured":"Morrow M, Horton S, Kioussis D, Brady HJM, Williams O. TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood. 2004;103:3890\u20136.","journal-title":"Blood"},{"key":"2683_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ng.2874","volume":"46","author":"E Papaemmanuil","year":"2014","unstructured":"Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014;46:116\u201325.","journal-title":"Nat Genet"},{"key":"2683_CR15","doi-asserted-by":"publisher","first-page":"e13087","DOI":"10.7554\/eLife.13087","volume":"5","author":"M Hein\u00e4niemi","year":"2016","unstructured":"Hein\u00e4niemi M, Vuorenmaa T, Teppo S, Kaikkonen MU, Bouvy-Liivrand M, Mehtonen J, et al. Transcription-coupled genetic instability marks acute lymphoblastic leukemia structural variation hotspots. Elife. 2016;5:e13087.","journal-title":"Elife"},{"key":"2683_CR16","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1093\/hmg\/ddq224","volume":"19","author":"H Lilljebj\u00f6rn","year":"2010","unstructured":"Lilljebj\u00f6rn H, Soneson C, Andersson A, Heldrup J, Behrendtz M, Kawamata N, et al. The correlation pattern of acquired copy number changes in 164 ETV6\/RUNX1-positive childhood acute lymphoblastic leukemias. Hum Mol Genet. 2010;19:3150\u20138.","journal-title":"Hum Mol Genet"},{"key":"2683_CR17","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54:1376\u201389.","journal-title":"Nat Genet"},{"key":"2683_CR18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature05690","volume":"446","author":"CG Mullighan","year":"2007","unstructured":"Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758\u201364.","journal-title":"Nature"},{"key":"2683_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415\u201321.","journal-title":"Nature"},{"key":"2683_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7604","volume":"6","author":"X Ma","year":"2015","unstructured":"Ma X, Edmonson M, Yergeau D, Muzny DM, Hampton OA, Rusch M, et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun. 2015;6:6604.","journal-title":"Nat Commun"},{"key":"2683_CR21","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41568-021-00377-7","volume":"21","author":"G Koh","year":"2021","unstructured":"Koh G, Degasperi A, Zou X, Momen S, Nik-Zainal S. Mutational signatures: emerging concepts, caveats and clinical applications. Nat Rev Cancer. 2021;21:619\u201337.","journal-title":"Nat Rev Cancer"},{"key":"2683_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/0008-5472.BCD-19-0041","volume":"1","author":"E Waanders","year":"2020","unstructured":"Waanders E, Gu Z, Dobson SM, Anti\u0107 \u017d, Crawford JC, Ma X, et al. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. Blood Cancer Discov. 2020;1:96\u2013111.","journal-title":"Blood Cancer Discov"},{"key":"2683_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/genes12020214","volume":"12","author":"\u017d Anti\u0107","year":"2021","unstructured":"Anti\u0107 \u017d, Lelieveld SH, van der Ham CG, Sonneveld E, Hoogerbrugge PM, Kuiper RP. Unravelling the sequential interplay of mutational mechanisms during clonal evolution in relapsed pediatric acute lymphoblastic leukemia. Genes (Basel). 2021;12:214.","journal-title":"Genes (Basel)"},{"key":"2683_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95109-0","volume":"11","author":"S Sayyab","year":"2021","unstructured":"Sayyab S, Lundmark A, Larsson M, Ringn\u00e9r M, Nystedt S, Marincevic-Zuniga Y, et al. Mutational patterns and clonal evolution from diagnosis to relapse in pediatric acute lymphoblastic leukemia. Sci Rep. 2021;11:15988.","journal-title":"Sci Rep"},{"key":"2683_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s42003-020-01119-5","volume":"3","author":"VK Singh","year":"2020","unstructured":"Singh VK, Rastogi A, Hu X, Wang Y, De S. Mutational signature SBS8 predominantly arises due to late replication errors in cancer. Commun Biol. 2020;3:421.","journal-title":"Commun Biol"},{"key":"2683_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21891-0","volume":"12","author":"A Langenbucher","year":"2021","unstructured":"Langenbucher A, Bowen D, Sakhtemani R, Bournique E, Wise JF, Zou L, et al. An extended APOBEC3A mutation signature in cancer. Nat Commun. 2021;12:1602.","journal-title":"Nat Commun"},{"key":"2683_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-05867-0","volume":"14","author":"C Zong","year":"2023","unstructured":"Zong C, Zhang Z, Gao L, He J, Wang Y, Li Q, et al. APOBEC3B coordinates R-loop to promote replication stress and sensitize cancer cells to ATR\/Chk1 inhibitors. Cell Death Dis. 2023;14:1\u201312.","journal-title":"Cell Death Dis"},{"key":"2683_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1042-9","volume":"17","author":"N Kanu","year":"2016","unstructured":"Kanu N, Cerone MA, Goh G, Zalmas LP, Bartkova J, Dietzen M, et al. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biol. 2016;17:185.","journal-title":"Genome Biol"},{"key":"2683_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-022-01316-0","volume":"20","author":"GM Jakobsdottir","year":"2022","unstructured":"Jakobsdottir GM, Brewer DS, Cooper C, Green C, Wedge DC. APOBEC3 mutational signatures are associated with extensive and diverse genomic instability across multiple tumour types. BMC Biol. 2022;20:117.","journal-title":"BMC Biol"},{"key":"2683_CR30","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/nar\/gky1316","volume":"47","author":"JCF Ng","year":"2019","unstructured":"Ng JCF, Quist J, Grigoriadis A, Malim MH, Fraternali F. Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases. Nucleic Acids Res. 2019;47:1178\u201394.","journal-title":"Nucleic Acids Res"},{"key":"2683_CR31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.bbrc.2021.02.008","volume":"546","author":"S Hirabayashi","year":"2021","unstructured":"Hirabayashi S, Shirakawa K, Horisawa Y, Matsumoto T, Matsui H, Yamazaki H, et al. APOBEC3B is preferentially expressed at the G2\/M phase of cell cycle. Biochemical Biophysical Res Commun. 2021;546:178\u201384.","journal-title":"Biochemical Biophysical Res Commun"},{"key":"2683_CR32","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1016\/j.celrep.2019.05.004","volume":"27","author":"MC Cuiti\u00f1o","year":"2019","unstructured":"Cuiti\u00f1o MC, P\u00e9cot T, Sun D, Kladney R, Okano-Uchida T, Shinde N, et al. Two distinct E2F transcriptional modules drive cell cycles and differentiation. Cell Rep. 2019;27:3547\u20133560.e5.","journal-title":"Cell Rep."},{"key":"2683_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00799-2","volume":"12","author":"J Mehtonen","year":"2020","unstructured":"Mehtonen J, Teppo S, Lahnalampi M, Kokko A, Kaukonen R, Oksa L, et al. Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities. Genome Med. 2020;12:99.","journal-title":"Genome Med"},{"key":"2683_CR34","doi-asserted-by":"crossref","unstructured":"Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, Williams RS, et al. E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev. 1998;12:2120\u201330.","DOI":"10.1101\/gad.12.14.2120"},{"key":"2683_CR35","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1182\/blood.2020009564","volume":"137","author":"R Somasundaram","year":"2021","unstructured":"Somasundaram R, Jensen CT, Tingvall-Gustafsson J, \u00c5hsberg J, Okuyama K, Prasad M, et al. EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene. Blood. 2021;137:3037\u201349.","journal-title":"Blood"},{"key":"2683_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56229-7","volume":"16","author":"Z Li","year":"2025","unstructured":"Li Z, Zhao H, Yang W, Maillard M, Yoshimura S, Hsiao YC, et al. Molecular and pharmacological heterogeneity of ETV6::RUNX1 acute lymphoblastic leukemia. Nat Commun. 2025;16:1153.","journal-title":"Nat Commun"},{"key":"2683_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1146\/annurev.biochem.71.090501.150203","volume":"71","author":"M Gellert","year":"2002","unstructured":"Gellert M. V(D)J recombination: RAG proteins, repair factors, and regulation. Annu Rev Biochem. 2002;71:101\u201332.","journal-title":"Annu Rev Biochem"},{"key":"2683_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri2491","volume":"9","author":"S Herzog","year":"2009","unstructured":"Herzog S, Reth M, Jumaa H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol. 2009;9:195\u2013205.","journal-title":"Nat Rev Immunol"},{"key":"2683_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev-genet-110410-132552","volume":"45","author":"DG Schatz","year":"2011","unstructured":"Schatz DG, Swanson PC. V(D)J recombination: mechanisms of initiation. Annu Rev Genet. 2011;45:167\u2013202.","journal-title":"Annu Rev Genet"},{"key":"2683_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17095-7","volume":"11","author":"F Nadeu","year":"2020","unstructured":"Nadeu F, Mas-de-les-Valls R, Navarro A, Royo R, Mart\u00edn S, Villamor N, et al. IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. Nat Commun. 2020;11:3390.","journal-title":"Nat Commun"},{"key":"2683_CR41","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/sj.leu.2402475","volume":"16","author":"VHJ van der Velden","year":"2002","unstructured":"van der Velden VHJ, Willemse MJ, van der Schoot CE, H\u00e4hlen K, van Wering ER, van Dongen JJM. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia. 2002;16:928\u201336.","journal-title":"Leukemia"},{"key":"2683_CR42","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1038\/sj.leu.2400904","volume":"11","author":"A Beishuizen","year":"1997","unstructured":"Beishuizen A, de Bruijn MA, Pongers-Willemse MJ, Verhoeven MA, van Wering ER, H\u00e4hlen K, et al. Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease. Leukemia. 1997;11:2200\u20137.","journal-title":"Leukemia"},{"key":"2683_CR43","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s43018-020-00124-1","volume":"1","author":"K Oshima","year":"2020","unstructured":"Oshima K, Zhao J, P\u00e9rez-Dur\u00e1n P, Brown JA, Pati\u00f1o-Galindo JA, Chu T, et al. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nat Cancer. 2020;1:1113\u201327.","journal-title":"Nat Cancer"},{"key":"2683_CR44","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1073\/pnas.1816254116","volume":"116","author":"C Poulard","year":"2019","unstructured":"Poulard C, Kim HN, Fang M, Kruth K, Gagnieux C, Gerke DS, et al. Relapse-associated AURKB blunts the glucocorticoid sensitivity of B cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2019;116:3052\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2683_CR45","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1182\/bloodadvances.2019001307","volume":"4","author":"H Ueno","year":"2020","unstructured":"Ueno H, Yoshida K, Shiozawa Y, Nannya Y, Iijima-Yamashita Y, Kiyokawa N, et al. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2020;4:5165\u201373.","journal-title":"Blood Adv"},{"key":"2683_CR46","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.V124.21.791.791","volume":"124","author":"JJ Yang","year":"2014","unstructured":"Yang JJ, Xu H, Bhojwani D, Moriyama T, Qian M, Yang X, et al. ARID5B regulates leukemia sensitivity to antimetabolites in children with acute lymphoblastic leukemia via effects on cell cycle progression. Blood. 2014;124:791.","journal-title":"Blood"},{"key":"2683_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood.2019002220","volume":"135","author":"B Li","year":"2020","unstructured":"Li B, Brady SW, Ma X, Shen S, Zhang Y, Li Y, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135:41\u201355.","journal-title":"Blood"},{"key":"2683_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01570-8","volume":"20","author":"J Tao","year":"2020","unstructured":"Tao J, Sun D, Dong L, Zhu H, Hou H. Advancement in research and therapy of NF1 mutant malignant tumors. Cancer Cell Int. 2020;20:492.","journal-title":"Cancer Cell Int"},{"key":"2683_CR49","doi-asserted-by":"publisher","first-page":"8921","DOI":"10.18632\/oncotarget.13475","volume":"8","author":"K Hientz","year":"2016","unstructured":"Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2016;8:8921\u201346.","journal-title":"Oncotarget"},{"key":"2683_CR50","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/leu.2014.80","volume":"28","author":"IM Ari\u00ebs","year":"2014","unstructured":"Ari\u00ebs IM, Jerchel IS, van den Dungen RESR, van den Berk LCJ, Boer JM, Horstmann MA, et al. EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion. Leukemia. 2014;28:1828\u201337.","journal-title":"Leukemia"},{"key":"2683_CR51","doi-asserted-by":"crossref","unstructured":"Singh J, Kumari S, Arora M, Verma D, Palanichamy JK, Kumar R, et al. Prognostic relevance of expression of EMP1, CASP1, and NLRP3 genes in pediatric B-lineage acute lymphoblastic leukemia. Front Oncol. 2021;11:606370.","DOI":"10.3389\/fonc.2021.606370"},{"key":"2683_CR52","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1002\/ctd2.100","volume":"2","author":"S Marimuthu","year":"2022","unstructured":"Marimuthu S, Batra SK, Ponnusamy MP. Pan-cancer analysis of altered glycosyltransferases confers poor clinical outcomes. Clinical Transl Discov. 2022;2:e100.","journal-title":"Clinical Transl Discov"},{"key":"2683_CR53","first-page":"2284","volume":"8","author":"X Ma","year":"2018","unstructured":"Ma X, Qi W, Pan H, Yang F, Deng J. Overexpression of USP5 contributes to tumorigenesis in non-small cell lung cancer via the stabilization of \u03b2-catenin protein. Am J Cancer Res. 2018;8:2284\u201395.","journal-title":"Am J Cancer Res"},{"key":"2683_CR54","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3389\/fonc.2019.01258","volume":"9","author":"Z Liu","year":"2019","unstructured":"Liu Z, Wu Y, Zhang Y, Yuan M, Li X, Gao J, et al. TIGAR Promotes Tumorigenesis and Protects Tumor Cells From Oxidative and Metabolic Stresses in Gastric Cancer. Front Oncol. 2019;9:1258.","journal-title":"Front Oncol"},{"key":"2683_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00220-9","volume":"5","author":"W Dai","year":"2020","unstructured":"Dai W, Xu Y, Mo S, Li Q, Yu J, Wang R, et al. GLUT3 induced by AMPK\/CREB1 axis is key for withstanding energy stress and augments the efficacy of current colorectal cancer therapies. Sig Transduct Target Ther. 2020;5:1\u201314.","journal-title":"Sig Transduct Target Ther"},{"key":"2683_CR56","doi-asserted-by":"publisher","first-page":"9021","DOI":"10.1002\/jcp.29753","volume":"235","author":"GC Ziegler","year":"2020","unstructured":"Ziegler GC, Almos P, McNeill RV, Jansch C, Lesch KP. Cellular effects and clinical implications of SLC2A3 copy number variation. J Cell Physiol. 2020;235:9021\u201336.","journal-title":"J Cell Physiol"},{"key":"2683_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35793-2","volume":"13","author":"B Yan","year":"2023","unstructured":"Yan B, Guo J, Deng S, Chen D, Huang M. A pan-cancer analysis of the role of USP5 in human cancers. Sci Rep. 2023;13:8972.","journal-title":"Sci Rep"},{"key":"2683_CR58","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1038\/s12276-022-00902-0","volume":"54","author":"J Yoo","year":"2022","unstructured":"Yoo J, Kim GW, Jeon YH, Kim JY, Lee SW, Kwon SH. Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis. Exp Mol Med. 2022;54:2107\u201317.","journal-title":"Exp Mol Med"},{"key":"2683_CR59","doi-asserted-by":"publisher","first-page":"113855","DOI":"10.1016\/j.ejmech.2021.113855","volume":"226","author":"GJ Yang","year":"2021","unstructured":"Yang GJ, Wu J, Miao L, Zhu MH, Zhou QJ, Lu XJ, et al. Pharmacological inhibition of KDM5A for cancer treatment. European J Medicinal Chem. 2021;226:113855.","journal-title":"European J Medicinal Chem"},{"key":"2683_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-05575-9","volume":"14","author":"L Ren","year":"2023","unstructured":"Ren L, Meng L, Gao J, Lu M, Guo C, Li Y, et al. PHB2 promotes colorectal cancer cell proliferation and tumorigenesis through NDUFS1-mediated oxidative phosphorylation. Cell Death Dis. 2023;14:1\u201311.","journal-title":"Cell Death Dis"},{"key":"2683_CR61","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/leu.2017.303","volume":"32","author":"IS Jerchel","year":"2018","unstructured":"Jerchel IS, Hoogkamer AQ, Ari\u00ebs IM, Steeghs EMP, Boer JM, Besselink NJM, et al. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia. Leukemia. 2018;32:931\u201340.","journal-title":"Leukemia"},{"key":"2683_CR62","doi-asserted-by":"publisher","first-page":"11306","DOI":"10.1073\/pnas.1608420113","volume":"113","author":"K Oshima","year":"2016","unstructured":"Oshima K, Khiabanian H, da Silva-Almeida AC, Tzoneva G, Abate F, Ambesi-Impiombato A, et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2016;113:11306\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2683_CR63","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2009.05.006","volume":"137","author":"J Luo","year":"2009","unstructured":"Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009;137:835\u201348.","journal-title":"Cell"},{"key":"2683_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30582-3","volume":"13","author":"J Levati\u0107","year":"2022","unstructured":"Levati\u0107 J, Salvadores M, Fuster-Tormo F, Supek F. Mutational signatures are markers of drug sensitivity of cancer cells. Nat Commun. 2022;13:2926.","journal-title":"Nat Commun"},{"key":"2683_CR65","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1158\/1078-0432.CCR-22-2861","volume":"29","author":"PA Roelofs","year":"2023","unstructured":"Roelofs PA, Martens JWM, Harris RS, Span PN. Clinical implications of APOBEC3-mediated mutagenesis in breast cancer. Clin Cancer Res. 2023;29:1658\u201369.","journal-title":"Clin Cancer Res"},{"key":"2683_CR66","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41588-023-01592-8","volume":"56","author":"DR Caswell","year":"2024","unstructured":"Caswell DR, Gui P, Mayekar MK, Law EK, Pich O, Bailey C, et al. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. Nat Genet. 2024;56:60\u201373.","journal-title":"Nat Genet"},{"key":"2683_CR67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-023-01425-5","volume":"16","author":"K Butler","year":"2023","unstructured":"Butler K, Banday AR. APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential. Journal Hematol Oncol. 2023;16:31.","journal-title":"Journal Hematol Oncol"},{"key":"2683_CR68","doi-asserted-by":"publisher","first-page":"12099","DOI":"10.1074\/jbc.RA119.008443","volume":"294","author":"JL McCann","year":"2019","unstructured":"McCann JL, Klein MM, Leland EM, Law EK, Brown WL, Salamango DJ, et al. The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1. Journal Biol Chem. 2019;294:12099.","journal-title":"Journal Biol Chem"},{"key":"2683_CR69","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1158\/2159-8290.CD-20-0725","volume":"11","author":"S Venkatesan","year":"2021","unstructured":"Venkatesan S, Angelova M, Puttick C, Zhai H, Caswell DR, Lu WT, et al. Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. Cancer Discov. 2021;11:2456\u201373.","journal-title":"Cancer Discov"},{"key":"2683_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38456-y","volume":"14","author":"J Sarno","year":"2023","unstructured":"Sarno J, Domizi P, Liu Y, Merchant M, Pedersen CB, Jedoui D, et al. Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia. Nat Commun. 2023;14:2935.","journal-title":"Nat Commun"},{"key":"2683_CR71","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1309\/WTXCQ5NRACVXTYBY","volume":"121","author":"R Kansal","year":"2004","unstructured":"Kansal R, Deeb G, Barcos M, Wetzler M, Brecher ML, Block AW, et al. Precursor B lymphoblastic leukemia with surface light chain immunoglobulin restriction: a report of 15 patients. Am J Clin Pathol. 2004;121:512\u201325.","journal-title":"Am J Clin Pathol"},{"key":"2683_CR72","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature09883","volume":"473","author":"C Duy","year":"2011","unstructured":"Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011;473:384\u20138.","journal-title":"Nature"},{"key":"2683_CR73","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1182\/blood-2015-01-567842","volume":"125","author":"M M\u00fcschen","year":"2015","unstructured":"M\u00fcschen M. Rationale for targeting the pre\u2013B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood. 2015;125:3688\u201393.","journal-title":"Blood"},{"key":"2683_CR74","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1084\/jem.20091299","volume":"207","author":"C Duy","year":"2010","unstructured":"Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, et al. BCL6 is critical for the development of a diverse primary B cell repertoire. Journal Exp Med. 2010;207:1209\u201321.","journal-title":"Journal Exp Med"},{"key":"2683_CR75","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/cancers14040860","volume":"14","author":"N Profit\u00f3s-Pelej\u00e0","year":"2022","unstructured":"Profit\u00f3s-Pelej\u00e0 N, Santos JC, Mar\u00edn-Niebla A, Rou\u00e9 G, Ribeiro ML. Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas. Cancers (Basel). 2022;14:860.","journal-title":"Cancers (Basel)"},{"key":"2683_CR76","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41422-020-0328-3","volume":"30","author":"X Liu","year":"2020","unstructured":"Liu X, Liu T, Shang Y, Dai P, Zhang W, Lee BJ, et al. ERCC6L2 promotes DNA orientation-specific recombination in mammalian cells. Cell Res. 2020;30:732\u201344.","journal-title":"Cell Res"},{"key":"2683_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-024-03260-4","volume":"25","author":"A Malyukova","year":"2024","unstructured":"Malyukova A, Lahnalampi M, Falqu\u00e9s-Costa T, P\u00f6l\u00f6nen P, Sipola M, Mehtonen J, et al. Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia. Genome Biol. 2024;25:143.","journal-title":"Genome Biol"},{"key":"2683_CR78","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1158\/1078-0432.CCR-19-0190","volume":"26","author":"H Xu","year":"2020","unstructured":"Xu H, Zhao X, Bhojwani D, E S, Goodings C, Zhang H, et al. ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. Clin Cancer Res. 2020;26:256\u201364.","journal-title":"Clin Cancer Res"},{"key":"2683_CR79","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/sj.leu.2404083","volume":"20","author":"WaG Stams","year":"2006","unstructured":"Stams WaG, Beverloo HB, den Boer ML, de Menezes RX, Stigter RL, van Drunen E, et al. Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome. Leukemia. 2006;20:410\u20136.","journal-title":"Leukemia"},{"key":"2683_CR80","unstructured":"Chang TC, Chen W, Qu C, Cheng Z, Hedges D, Elsayed A, et al. Genomic determinants of outcome in acute lymphoblastic leukemia. JCO. 2024;JCO.23.02238."},{"key":"2683_CR81","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cancergencyto.2005.02.019","volume":"162","author":"Y Alvarez","year":"2005","unstructured":"Alvarez Y, Coll MD, Ortega JJ, Bastida P, Dastugue N, Robert A, et al. Genetic abnormalities associated with the t(12;21) and their impact in the outcome of 56 patients with B-precursor acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2005;162:21\u20139.","journal-title":"Cancer Genet Cytogenet"},{"key":"2683_CR82","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/sj.leu.2404507","volume":"21","author":"A Attarbaschi","year":"2007","unstructured":"Attarbaschi A, Mann G, Strehl S, K\u00f6nig M, Steiner M, Jeitler V, et al. Deletion of 11q23 is a highly specific nonrandom secondary genetic abnormality of ETV6\/RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia. 2007;21:584\u20136.","journal-title":"Leukemia"},{"key":"2683_CR83","first-page":"186532","volume":"2012","author":"MAF Hernandes","year":"2012","unstructured":"Hernandes MAF, Marques-Salles T, de J, Mkrtchyan H, Soares-Ventura EM, Leite EP, et al. Extra Copies of der(21)t(12;21) plus Deletion of ETV6 Gene due to dic(12;18) in B-Cell Precursor ALL with Poor Outcome. Case Rep. Genet. 2012;2012:186532.","journal-title":"Case Rep. Genet"},{"key":"2683_CR84","doi-asserted-by":"publisher","first-page":"35445","DOI":"10.18632\/oncotarget.16367","volume":"8","author":"C Sun","year":"2017","unstructured":"Sun C, Chang L, Zhu X. Pathogenesis of ETV6\/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse. Oncotarget. 2017;8:35445\u201359.","journal-title":"Oncotarget"},{"key":"2683_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13331","volume":"7","author":"Z Gu","year":"2016","unstructured":"Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, et al. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016;7:13331.","journal-title":"Nat Commun"},{"key":"2683_CR86","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ydbio.2012.04.023","volume":"366","author":"B Lee","year":"2012","unstructured":"Lee B, Rizzoti K, Kwon DS, Kim SY, Oh S, Epstein DJ, et al. Direct transcriptional regulation of Six6 is controlled by SoxB1 binding to a remote forebrain enhancer. Dev Biol. 2012;366:393\u2013403.","journal-title":"Dev Biol"},{"key":"2683_CR87","doi-asserted-by":"publisher","first-page":"10927","DOI":"10.1073\/pnas.1821301116","volume":"116","author":"T Arends","year":"2019","unstructured":"Arends T, Dege C, Bortnick A, Danhorn T, Knapp JR, Jia H, et al. CHD4 is essential for transcriptional repression and lineage progression in B lymphopoiesis. Proc Natl Acad Sci USA. 2019;116:10927\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2683_CR88","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.celrep.2019.04.011","volume":"27","author":"WF Yen","year":"2019","unstructured":"Yen WF, Sharma R, Cols M, Lau CM, Chaudhry A, Chowdhury P, et al. Distinct requirements of CHD4 during B cell development and antibody response. Cell Rep. 2019;27:1472\u20131486.e5.","journal-title":"Cell Rep"},{"key":"2683_CR89","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/ijc.31881","volume":"144","author":"J Plch","year":"2019","unstructured":"Plch J, Hrabeta J, Eckschlager T. KDM5 demethylases and their role in cancer cell chemoresistance. International J Cancer. 2019;144:221\u201331.","journal-title":"International J Cancer"},{"key":"2683_CR90","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0301-472X(00)00620-2","volume":"29","author":"S Tokimasa","year":"2001","unstructured":"Tokimasa S, Ohta H, Sawada A, Matsuda Y, Kim JY, Nishiguchi S, et al. Lack of the Polycomb-group gene rae28 causes maturation arrest at the early B-cell developmental stage. Experimental Hematol. 2001;29:93\u2013103.","journal-title":"Experimental Hematol"},{"key":"2683_CR91","doi-asserted-by":"publisher","first-page":"e202302481","DOI":"10.26508\/lsa.202302481","volume":"7","author":"M Lysenkova Wiklander","year":"2024","unstructured":"Lysenkova Wiklander M, Arvidsson G, Bunikis I, Lundmark A, Raine A, Marincevic-Zuniga Y, et al. A multiomic characterization of the leukemia cell line REH using short- and long-read sequencing. Life Sci Alliance. 2024;7:e202302481.","journal-title":"Life Sci Alliance"},{"key":"2683_CR92","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood-2021-150086","volume":"138","author":"SL Heatley","year":"2021","unstructured":"Heatley SL, Page EC, Eadie LN, McClure BJ, Rehn J, Yeung DT, et al. Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis. Blood. 2021;138:1317.","journal-title":"Blood"},{"key":"2683_CR93","doi-asserted-by":"crossref","unstructured":"Wen R, Chen Y, Schuman J, Fu G, Yang S, Zhang W, et al. An important role of phospholipase C\u03b31 in pre-B-cell development and allelic exclusion. EMBO J. 2004. https:\/\/www.embopress.org\/doi\/10.1038\/sj.emboj.7600405.","DOI":"10.1038\/sj.emboj.7600405"},{"key":"2683_CR94","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"2683_CR95","doi-asserted-by":"crossref","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","DOI":"10.1126\/scisignal.2004088"},{"key":"2683_CR96","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal. Cancer Res. 2023;83:3861\u20137.","journal-title":"Cancer Res"},{"key":"2683_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-023-00479-5","volume":"7","author":"O Krali","year":"2023","unstructured":"Krali O, Marincevic-Zuniga Y, Arvidsson G, Enblad AP, Lundmark A, Sayyab S, et al. Multimodal classification of molecular subtypes in pediatric acute lymphoblastic leukemia. npj Precis Onc. 2023;7:1\u201313.","journal-title":"npj Precis Onc"},{"key":"2683_CR98","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/leu.2017.265","volume":"32","author":"N Toft","year":"2018","unstructured":"Toft N, Birgens H, Abrahamsson J, Gri\u0161kevi\u010dius L, Hallb\u00f6\u00f6k H, Heyman M, et al. Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606\u201315.","journal-title":"Leukemia"},{"key":"2683_CR99","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/leu.2009.251","volume":"24","author":"K Schmiegelow","year":"2010","unstructured":"Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, S\u00f6derh\u00e4ll S, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24:345\u201354.","journal-title":"Leukemia"},{"key":"2683_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45839-z","volume":"9","author":"HM Amemiya","year":"2019","unstructured":"Amemiya HM, Kundaje A, Boyle AP. The ENCODE blacklist: identification of problematic regions of the genome. Sci Rep. 2019;9:9354.","journal-title":"Sci Rep"},{"key":"2683_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-014-0039-z","volume":"7","author":"J Nordlund","year":"2015","unstructured":"Nordlund J, B\u00e4cklin CL, Zachariadis V, Cavelier L, Dahlberg J, \u00d6fverholm I, et al. DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia. Clin Epigenetics. 2015;7:11.","journal-title":"Clin Epigenetics"},{"key":"2683_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2013-14-9-r105","volume":"14","author":"J Nordlund","year":"2013","unstructured":"Nordlund J, B\u00e4cklin CL, Wahlberg P, Busche S, Berglund EC, Eloranta ML, et al. Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia. Genome Biol. 2013;14:r105.","journal-title":"Genome Biol"},{"key":"2683_CR103","unstructured":"Davis S, Du P, Bilke S, Triche T, Jr, Bootwalla M. methylumi: Handle Illumina methylation data [Internet]. Bioconductor version: Release (3.17); 2023 [cited 2023 Jul 31]. Available from: https:\/\/bioconductor.org\/packages\/methylumi\/."},{"key":"2683_CR104","unstructured":"Hovestadt V, Zapatka M. conumee: Enhanced copy-number variation analysis using Illumina DNA methylation arrays [Internet]. Bioconductor version: Release (3.17); 2023 [cited 2023 Jul 31]. Available from: https:\/\/bioconductor.org\/packages\/conumee\/."},{"key":"2683_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-018-2234-y","volume":"19","author":"M D\u00edaz-Gay","year":"2018","unstructured":"D\u00edaz-Gay M, Vila-Casades\u00fas M, Franch-Exp\u00f3sito S, Hern\u00e1ndez-Ill\u00e1n E, Lozano JJ, Castellv\u00ed-Bel S. Mutational Signatures in Cancer (MuSiCa): a web application to implement mutational signatures analysis in cancer samples. BMC Bioinforma. 2018;19:224.","journal-title":"BMC Bioinforma"},{"key":"2683_CR106","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btad756","volume":"39","author":"M D\u00edaz-Gay","year":"2023","unstructured":"D\u00edaz-Gay M, Vangara R, Barnes M, Wang X, Islam SMA, Vermes I, et al. Assigning mutational signatures to individual samples and individual somatic mutations with SigProfilerAssignment. Bioinformatics. 2023;39:btad756.","journal-title":"Bioinformatics"},{"key":"2683_CR107","doi-asserted-by":"crossref","unstructured":"Ewels PA, Peltzer A, Fillinger S, Alneberg J, Patel H, Wilm A, et al. nf-core: Community curated bioinformatics pipelines [Internet]. bioRxiv; 2019. 610741. https:\/\/www.biorxiv.org\/content\/10.1101\/610741v1.","DOI":"10.1101\/610741"},{"key":"2683_CR108","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"2683_CR109","doi-asserted-by":"crossref","unstructured":"Enblad AP, Krali O, Gezelius H, Lundmark A, Blom K, Andersson C, et al. Ex Vivo Drug Responses and Molecular Profiles of 597 Pediatric Acute Lymphoblastic Leukemia Patients [Internet]. medRxiv; 2024 [cited 2025 Jan 14]. p. 2024.12.17.24319138. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2024.12.17.24319138v1.","DOI":"10.1101\/2024.12.17.24319138"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02683-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02683-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02683-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:21:20Z","timestamp":1757218880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02683-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":109,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2683"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02683-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}